Results 181 to 190 of about 4,590 (196)
Some of the next articles are maybe not open access.
Insulin Glargine Use During Pregnancy
Endocrine Practice, 2011To review the literature regarding the use of insulin glargine during pregnancy, specifically addressing the issues and concerns surrounding mitogenicity, placental transfer, and maternal and fetal safety.We performed a systematic literature search using MEDLINE and BIOSIS Previews up to March 2011.
Kevin M. Pantalone +2 more
openaire +3 more sources
Insulin glargine: A new long-acting insulin product
American Journal of Health-System Pharmacy, 2002The pharmacodynamics, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of insulin glargine are reviewed. Current treatment regimens for patients with type 1 diabetes mellitus and some with type 2 are designed to provide a basal insulin level with intermittent preprandial insulin coverage. Insulin glargine precipitates
Lindsey Reinhart, Chad A. Panning
openaire +3 more sources
Study of the Aggregation of Insulin Glargine by Light Scattering
Journal of Pharmaceutical Sciences, 2006Insulin glargine (Lantus, Aventis Pharma, Deutschland, GmbH) is a new long-acting human insulin analog. Structural modification of the insulin molecule at two sites alters its pH, causing insulin glargine to precipitate in the neutral environment of subcutaneous tissue and to form a depot that is slowly absorbed into the bloodstream.
R Coppolino, S Coppolino, V Villari
openaire +4 more sources
Annals of Pharmacotherapy, 2020
Background: Basaglar, insulin glargine (BGlar; Eli Lilly, Indianapolis, IN), a follow-on biologic, was developed after the patent for Lantus, insulin glargine (LGlar; Sanofi-Aventis, Paris, France) expired. Objective: To compare the dosing and hemoglobin A1C (A1C)-lowering effects of BGlar compared with LGlar in a real-world setting.
Jamie M. Pitlick +7 more
openaire +2 more sources
Background: Basaglar, insulin glargine (BGlar; Eli Lilly, Indianapolis, IN), a follow-on biologic, was developed after the patent for Lantus, insulin glargine (LGlar; Sanofi-Aventis, Paris, France) expired. Objective: To compare the dosing and hemoglobin A1C (A1C)-lowering effects of BGlar compared with LGlar in a real-world setting.
Jamie M. Pitlick +7 more
openaire +2 more sources
An Update on the Long‐Acting Insulin Analogue Glargine
Basic & Clinical Pharmacology & Toxicology, 2006Abstract: For both type 1 and type 2 diabetes, tight glycaemic control is vital to reduce the risk of long‐term complications. However, this must be achieved with minimal risk of hypoglycaemia. Glargine is a new long‐acting insulin analogue with an action profile designed to overcome this and has now been in clinical use for a number of years.
Henriette Thisted +3 more
openaire +4 more sources
Poisoning with Insulin Glargine
Clinical Toxicology, 2005Matjaz Bunc, Martin Mozina, Miran Brvar
openaire +2 more sources
Insulin Glargine and Cancer—An Unsubstantiated Allegation
Diabetes Technology & Therapeutics, 2009Jay S. Skyler +3 more
openaire +3 more sources
Insulin glargine and malignancy: an unwarranted alarm
The Lancet, 2009Liam Smeeth, Stuart J. Pocock
openaire +3 more sources
Insulin glargine: Basal insulin of choice?
American Journal of Health-System Pharmacy, 2002openaire +2 more sources